As of 31-Dec-2022, promoters held 46.83 per cent stake in the company, while FIIs held 13.81 per cent and domestic institutional investors had 16.44 per cent.

The stock quoted a 52-week high of Rs 946.5 and a 52-week low of Rs 583.05.

A total of 4,336 shares changed hands on the counter till 01:53PM (IST)

A total of 10,671 shares changed hands on the counter till 11:53AM (IST)

“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near term, there are multiple assets waiting to play out. For Cipla this year, we are hoping to see generic Advair, generic Abraxane which is most likely in the price but beyond that, there will be a generic Qvar, there will be a generic Teriparatide and potentially a generic Flovent as well.”

The stock traded at a P/E multiple of 488.21, while the price-to-book value ratio stood at 2.79.

“2023 was an overall good year. We expect a good stable year and from here, a lot of bottom up opportunities will come up in India across various sectors. If you look at the second quarter of FY23, it is proving that data point. I think there are many bottom up opportunities from here on. It is just the beginning of the growth cycle.”

On the technical charts, the 200-day moving average of the stock stood at Rs 691.51.

The stock quoted a 52-week high price of Rs 971.3 and a 52-week low of Rs 583.05.

“Being contrarian at any point in time is going to help as will value investing. So if there is value in auto, there is going to be growth and these are the companies which are going to drive the shift to EV as and when it comes. Over the next one year, pharma as a sector is going to throw up a lot of opportunities.”

The recent resurgence in Covid infections - against a backdrop of tightening monetary policies and hawkish commentaries by global central banks that could potentially trigger a global recession has dragged India's benchmark indices down by nearly 5% after hitting their all-time highs on December 1.

Indian companies have a very dominant market share given our low cost manufacturing base in India so I think on a broad basis most of the companies will see a very healthy profit recovery.

A total of 19,198 shares changed hands on the counter till 10:51AM (IST)

A total of 10,825 shares changed hands on the counter till 11:06AM (IST).

As of 30-Sep-2022, promoters held 46.83 per cent stake in the company, while FIIs held 13.81 per cent and domestic institutional investors had 16.44 per cent.

A total of 11,719 shares changed hands on the counter till 10:35AM (IST)

The stock quoted a 52-week high price of Rs 972.5 and a 52-week low of Rs 583.05.

On the technical charts, the RSI of the stock stood at 57.59.

As of 30-Sep-2022, promoters held 46.83 per cent stake in the company, while FIIs held 0.0 per cent and domestic institutional investors had 16.44 per cent.

A total of 4,400 shares changed hands on the counter till 12:23PM (IST).

On the technical charts, the RSI of the stock stood at 70.07.

As of 30-Sep-2022, promoters held 46.83 per cent stake in the company, while FIIs held 0.0 per cent and domestic institutional investors had 16.44 per cent.

The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” said Alexandre Franca, Managing Director, MedQuímica.

A total of 71,375 shares changed hands on the counter till 10:00AM (IST)

The USFDA has issued 8 observations for the drug product facility and API facility at Mandideep. The US drug regulator has inspected company's Mandideep unit-1 facility during November 14-23, 2022.

​Golden Cross is an important technical indicator of bullishness. It occurs when the short-term moving average crosses over the major long-term moving average on the upside.

The stock quoted a 52-week high of Rs 972.5 and a 52-week low of Rs 583.05.

Kaynes Technologies India is set to make its debut at the bourses on Tuesday after the company raised Rs 858 crore via its initial public offering between November 10-14 by selling the shares in the range of Rs 559-587 apeice.

“There is a tactical pullback in global denominated fintech and consumer tech business. Maybe a 10-15-20% move can be expected in some of the names but core allocation will have to be with largecaps, particularly sectors that have delivered well this year and where there is a growth visibility. That could be banks, auto, cement and the domestic-oriented consumption plays.”

"Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. "

"Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. "

Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 33693.66 Crore) operating in Pharmaceuticals sector.

Stocks that were in focus include names like Lupin which was up more than 3%, Adani Green which fell nearly 2% ahead of results, and Union Bank of India which closed with gains of over 4% on Thursday.

“One has to be very selective when it comes to pharma and focus on only a few players which have got the strategy right. One needs to find specialty niche products across the board in the global pharmaceutical market to survive and these companies have done so which is why I think investors are rewarding them. Going forward, that will also be the trend.”

Manufacturing and other expenses were 30% of sales at Rs 1,226.8 crore compared to Rs 1,191.6 crore in Q1 FY2023. Investment in R&D for the quarter was Rs 337.6 crore (8.3% of sales), Lupin said in a BSE filing.